(Q38062444)

28 August 2017

1 reference

title

Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? (English)

1 reference

28 August 2017

1

Gary Remington

1 reference

28 August 2017

2

Ofer Agid

1 reference

28 August 2017

3

George Foussias

1 reference

28 August 2017

5

Krysta McDonald

1 reference

28 August 2017

Larissa Ferguson

4

1 reference

28 August 2017

Valerie Powell

series ordinal

6

1 reference

28 August 2017

publication date

22 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

225

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

505-518

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-012-2922-7

28 August 2017

exact match

0 references

cites work

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Defining treatment refractoriness in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Ciprofloxacin strongly inhibits clozapine metabolism: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clinical and biochemical correlates of "high-dose" clozapine therapy for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Cytochrome P450 and therapeutic drug monitoring with respect to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine plasma level monitoring: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

The history of clozapine and its emergence in the US market: a review and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Infection-associated clozapine toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Update on the adverse effects of clozapine: focus on myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Serum antimuscarinic activity during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Modafinil-associated clozapine toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine toxicity associated with smoking cessation: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine-related seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Suspected clozapine poisoning in the UK/Eire, 1992-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Will routine therapeutic drug monitoring have a place in clozapine therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine-induced electroencephalogram changes as a function of clozapine serum levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Serum clozapine levels: a review of their clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Toxic rise of clozapine plasma concentrations in relation to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Patterns of clozapine prescribing in a mental health service in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Pharmacokinetics and pharmacodynamics of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Toxic clozapine serum levels during acute urinary tract infection: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Extrapyramidal symptoms after addition of fluvoxamine to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine: more than 900 mg/day may be needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Predictors of clinical outcome in schizophrenic patients responding to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine Tissue Concentrations following an Apparent Suicidal Overdose of Clozaril®

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Toxic clozapine serum levels during inflammatory reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Bacterial pneumonia can increase serum concentration of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine safety, 35 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Features and toxicokinetics of clozapine in overdose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Augmentation strategies in clozapine-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

High-dose clozapine intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Plasma level measurement in a patient with clozapine intoxication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Results of phase 3 of the CATIE schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Serum level of clozapine and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Clozapine-induced seizures: recognition and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2922-7

Therapeutic effect of clozapine at an unusually high plasma level

21 January 2018

1 reference

12 December 2020

Acute Clozapine Overdose: Plasma Concentration and Outcome

1 reference

12 December 2020

Clozapine: dangerous orphan or neglected friend?

1 reference

12 December 2020

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

1 reference

12 December 2020

Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations

1 reference

12 December 2020

N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia.

1 reference

12 December 2020

Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites

1 reference

12 December 2020

Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.

1 reference

12 December 2020

Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong.

1 reference

12 December 2020

Cognitive impairment among older adults with late-life schizophrenia or bipolar disorder

1 reference

12 December 2020

Effect of phenytoin on plasma clozapine concentrations in two patients

1 reference

12 December 2020

Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage

1 reference

12 December 2020

Elevated levels of clozapine in serum after addition of fluvoxamine

1 reference

12 December 2020

Therapeutic drug monitoring of clozapine: an unexpected outcome

1 reference

12 December 2020

Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

EEG alterations in patients treated with clozapine in relation to plasma levels

1 reference

12 December 2020

Elevated clozapine levels after fluvoxamine initiation

1 reference

12 December 2020

Erythromycin-induced clozapine toxic reaction

1 reference

12 December 2020

Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation

1 reference

12 December 2020

Seizure following addition of erythromycin to clozapine treatment

1 reference

12 December 2020

Fluvoxamine increases the clozapine serum levels significantly

1 reference

12 December 2020

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review

1 reference

12 December 2020

Contrasting clozapine prescribing patterns in the east and west?

1 reference

12 December 2020

Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking

1 reference

12 December 2020

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

1 reference

12 December 2020

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

1 reference

12 December 2020

Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study

1 reference

12 December 2020

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients

1 reference

12 December 2020

Optimizing clozapine treatment

1 reference

12 December 2020

Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia

1 reference

12 December 2020

The clinical use of plasma clozapine levels.

1 reference

12 December 2020

Elevated plasma levels of clozapine after concomitant use of fluvoxamine

1 reference

12 December 2020

Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner

1 reference

12 December 2020

Clozapine metabolism rate as a possible index of drug-induced granulocytopenia

1 reference

12 December 2020

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

12 December 2020

Elevated clozapine plasma concentrations after fluvoxamine initiation

1 reference

12 December 2020

Treatment-resistant schizophrenic patients

1 reference

12 December 2020

A fatal drug interaction between clozapine and fluoxetine

1 reference

12 December 2020

In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine

1 reference

12 December 2020

Clozapine plasma levels and convulsions

1 reference

12 December 2020

Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia

1 reference

12 December 2020

Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.

1 reference

12 December 2020

Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors

1 reference

12 December 2020

Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients

1 reference

12 December 2020

Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports

1 reference

12 December 2020

10.1007/S00213-012-2922-7

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1035795609

0 references

1 reference